Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Agios Pharm(AGIO)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for AGIO
09/25/2026: AGIO (1-star) is currently NOT-A-BUY. Pass it for now.
Agios Pharmaceuticals is a specialized biotechnology company that has successfully pivoted from oncology to focus on rare genetic metabolic disorders. Its primary growth driver is PYRUKYND, a first-in-class medicine targeting pyruvate kinase deficiency. While the company benefits from a solid balance sheet and a clear scientific focus, it faces execution risks regarding the commercial scaling of its lead product and the high binary uncertainty of its early-stage pipeline. The stock is best suited for growth-oriented investors who can tolerate the volatility associated with clinical-stage biotech and the competitive landscape for rare disease treatments. Investors should monitor ongoing clinical data readouts and updates on global market adoption.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers potential for significant growth through the expansion of its rare disease commercial portfolio. |
| Momentum investor | Mixed fit | Momentum depends on clinical data readouts and commercial launch acceleration. |
| Value investor | Weak fit | Valuation is often tied to future pipeline potential rather than current earnings or book value. |
| Dividend investor | Weak fit | The company does not pay dividends and prioritizes capital reinvestment. |
| Low-risk investor | Weak fit | Biotech stocks in the transition phase involve inherent clinical and regulatory risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is highly sensitive to clinical trial outcomes and regulatory news. |
| Valuation risk | Medium / high | Valuation relies on long-term growth assumptions that may not materialize. |
| Competition risk (rare disease specialists) | Medium | New therapeutic modalities could threaten the long-term positioning of current products. |
| Business quality | Medium | The company has strong scientific expertise but is still maturing its commercial infrastructure. |
| Dividend income | Low / none | Investors should not expect income from this investment. |
| Execution risk | Medium / high | Success depends on the effective identification and treatment of rare disease patients. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -59.73% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.96B USD | Price to earnings Ratio - | 1Y Target Price 46.25 |
Price to earnings Ratio - | 1Y Target Price 46.25 | ||
Volume (30-day avg) 926.4K shares | Beta 0.6 | 52 Weeks Range 22.24 - 46.00 | Updated Date 09/25/2026 |
52 Weeks Range 22.24 - 46.00 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.74 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Rare Disease Therapeutics | Revenue from sales of PYRUKYND (mitapivat) for the treatment of pyruvate kinase deficiency. | The company earns money primarily by selling a specialized drug to treat a rare blood disorder. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 2.47 | Enterprise Value 1.45B | Price to Sales(TTM) 19.97 |
Enterprise Value 1.45B | Price to Sales(TTM) 19.97 | ||
Enterprise Value to Revenue 14.79 | Enterprise Value to EBITDA -2.33 | Shares Outstanding 59.70M | Shares Floating 50.02M |
Shares Outstanding 59.70M | Shares Floating 50.02M | ||
Percent Insiders 1.07 | Percent Institutions 112.31 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Agios Pharm
Exchange NASDAQ | Headquarters Cambridge, MA, United States | ||
IPO Launch date 2013-07-24 | CEO & Director Mr. Brian M. Goff M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 539 | Website https://www.agios.com |
Full time employees 539 | Website https://www.agios.com | ||
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.